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ABSTRACT: Digital PCR (dPCR) has developed consid-
erably since the publication of the Minimum
Information for Publication of Digital PCR
Experiments (dMIQE) guidelines in 2013, with advan-
ces in instrumentation, software, applications, and our
understanding of its technological potential. Yet these
developments also have associated challenges; data
analysis steps, including threshold setting, can be diffi-
cult and preanalytical steps required to purify, concen-
trate, and modify nucleic acids can lead to measurement
error. To assist independent corroboration of conclu-
sions, comprehensive disclosure of all relevant experi-
mental details is required. To support the community
and reflect the growing use of dPCR, we present an up-
date to dMIQE, dMIQE2020, including a simplified
dMIQE table format to assist researchers in providing
key experimental information and understanding of the
associated experimental process. Adoption of
dMIQE2020 by the scientific community will assist in
standardizing experimental protocols, maximize efficient
utilization of resources, and further enhance the impact
of this powerful technology.
Introduction
Since the publication of the guidelines for the
Minimum Information for Publication of Quantitative
Digital PCR Experiments (dMIQE) (1), digital PCR
(dPCR) has seen considerable technological develop-
ment with a plethora of new applications. dPCR has
progressed from an expensive approach with a limited
application niche, available to only a few laboratories,
towards a mainstream global technology (2) offering
unique advantages and applications to many scientists.
To reflect this advancement, we present an update
to dMIQE, dMIQE2020, which builds on the original
guidelines to account for the increase in the number of
applications and new platforms that have become
available in the last 7 years. We highlight some of the as-
sociated advantages and limitations, and these updated
guidelines are written with the support of dPCR instru-
ment manufacturers (see Acknowledgment section).
The intention is to enable dMIQE2020 to reflect this
maturing technology by addressing new factors that
need to be included in publications reporting dPCR
data. We also present a revised simplified dMIQE table
format (Supplemental Table 1) to aid application and
increase adoption and provide an example of a com-
pleted table (Supplemental Table 2).
Description of the Method and Brief History
A dPCR reaction is performed using limiting dilution to
separate the nucleic acid molecules amongst a large
number of subreactions, termed partitions (Table 1 pro-
vides a summary of the terminology for dPCR). This
‘partitioning’ capitalizes on the random distribution of
nucleic acid molecules in solution, so that some of the
partitions contain single (or few) copies of target mole-
cules and, importantly, some contain none. Following
partitioning, the reaction, comprising all the partitions
to be analyzed, is subjected to PCR. Each dPCR parti-
tion contains the core reagents used in a real-time quan-
titative PCR (qPCR) reaction that will generate a
fluorescent signal in response to the presence of a target
sequence. A positive partition is identified by an in-
creased fluorescent intensity compared to a negative
partition with baseline signal only. Quantification is
performed by applying Poisson statistics to the propor-
tion of the negative partitions (typically calculated by
subtracting the number of positive partitions [k] from
the total number [n], see Equation 2 below) to account
for positive partitions that initially contained more than
one target molecule.
The concept of dPCR was developed before qPCR.
As early as 1988, just a few years after PCR was de-
scribed, Saiki et al. (3) applied limiting dilution to the
PCR, which was subsequently used to detect HIV DNA
(4). In the early 1990s, several articles were published
applying the concept mainly in the areas of virology,
lymphoid biology, and neoplasia (5). However, follow-
ing the initial description (6) and subsequent develop-
ment of qPCR, offering increasingly affordable, precise,
high-throughput, and multiplexed measurement of
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nucleic acids, resource intensive ‘limiting dilution PCR’
was eclipsed.
Development of the method did not completely
stop, however, with the term ‘digital PCR’ being coined
by Vogelstein and Kinzler in 1999 (7) as a method that
offered improved analytical sensitivity when measuring
mixtures of single nucleotide variants by PCR. This
concept was further advanced by developing BEAMing
(8) and its potential highlighted with some of the earli-
est circulating tumor DNA (ctDNA) measurement in
cancer patients (9). More recently, advances in micro-
fluidics have enabled the development of instruments
that can partition in very small volume formats.
Partitioning is currently achieved either through the
generation of water-in-oil droplets or using prefabricated
chips that contain solid chambers into which the reac-
tion is loaded.
Another development has been the establishment of
instruments with greater than 10,000 partitions per reac-
tion. These instruments can analyze tens of samples in a
single run typically providing 2- or 3-color formats allowing
for multiplexing, with more colors promised by manufac-
turers for future instruments. This contributes to improved
precision (Fig. 1A), increased dynamic range (Fig. 1B), and
increased analytical sensitivity due to the larger volume of
nucleic acids extract analyzed per reaction.
In parallel with hardware development, the expan-
sion of software tools (both vendor-specific and
Table 1. The meaning of frequently used terminology when discussing dPCR.
dPCR term Description Alternative name
prereaction the initial volume prepared prior to partitioning that contains mas-
ter mix, dNTPs, assay, and template
partition the subreaction used for limiting dilution and subsequently mea-
sured as positive or negative post reaction
droplet, chambera
n the total number of partitions used for quantification accepted partitions /droplets/
chambersa, analyzable parti-
tions/ droplets/chambersa
Vp the volume of each partition
reaction the total volume of the measured partitions (n x Vp)
dead volume difference between the volume of the prereaction and reaction
k the number of positive partitions in a reaction used for
quantification
w the number of negative partitions in a reaction used for
quantification
Poisson the statistical distribution used to account for the probability of a
partition initially containing more than one target
k lambda, the average number of target molecules per partition
fluorescence
intensity
the fluorescence of a partition fluorescence amplitude, end-
point fluorescence, relative
fluorescence unit
baseline the fluorescence of the negative partitions fluorescence noise/
background
peak resolution a measure of the separation in fluorescence between positive and
negative partitions
separability score, amplitude
threshold the line that separates the partition clusters based on amplitude
cluster the group of partitions that are located in a similar space within a
scatter plot based on amplitude
population, droplet
population
rain the partitions that are located within the space between the posi-
tive and negative clusters
higher
order
multiplexing
the term given to multiplexing that can count more targets than
there are fluorescent detection channels
intensity multiplexing
aThe term ‘chambers’ is used to define the partitions of instruments that use prefabricated chips, however this term is also used by some manufacturers to describe the reac-
tion vessel. Consequently, the use of the term ‘partition’ to describe dPCR subreactions is recommended as it is not used elsewhere when describing the technology and is ag-
nostic to the partitioning format of a given instrument.
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platform-independent) has given operators greater con-
trol of their analysis. Scatter plots that depict the end-
point fluorescence of each partition are now commonly
available. These plots also enable quality control checks
to be performed in parallel for individual reactions and
whole experiments. Other developments include the
ability to define thresholds that optimally separate posi-
tive and negative partitions, to combine different reac-
tions for greater sensitivity and higher precision, and to
export data to enable further analysis using third party
software.
Despite the increasing capabilities and use of
dPCR, many biological and clinical research scientists
are unclear as to what the practical advantages are.
Placed in the same methodological space as established
qPCR and the increasingly powerful massively parallel
(or next generation) sequencing, this is perhaps unsur-
prising. The reality is that dPCR provides a number of
unique opportunities. Here we explore recent develop-
ments and applications of dPCR, discuss the factors that
should be considered during the experimental design,
and detail considerations to be included in publications
reporting dPCR results.
An Overview of the Applications of dPCR
Recent uses of dPCR have spanned numerous DNA,
RNA, and epigenetic applications. A popular use of the
method is the detection and quantification of rare ge-
netic variants (e.g., single nucleotide variants) in mix-
tures of other, more predominant, variants of the same
sequence. Such ‘rare’ sequence detection can measure
actionable mutations in ctDNA (10), fetal genetic var-
iants in noninvasive prenatal testing (11), polymor-
phisms of a donor organ as an assessment of potential
graft rejection (12, 13), as well as rare bacterial geno-
types (14) and viral drug resistance (15). An example of
early direct clinical diagnostic application is the mea-
surement of ctDNA in liquid biopsies to guide the treat-
ment of non-small cell lung cancer (16, 17).
dPCR can offer greater precision than qPCR (18)
and is far simpler to use for copy number quantification
due the binary nature in which the partitions are
counted as positive or negative. The increased precision
of dPCR (18) enabled improved measurement of copy
number variants (19, 20), including in gene amplifica-
tion in neuroblastoma (21) and fetal trisomy by nonin-
vasive prenatal testing (22). dPCR also allows rare event
or trace level detection with high confidence since only
a single or small number of DNA molecules are ampli-
fied in each individual partition, regardless of whether
an experiment has 10 or 10 000 target molecules per re-
action. While qPCR can detect very low concentrations
of a target, calibration of trace measurements is chal-
lenging. This is one of the reasons dPCR has been
explored as a method for trace level measurements in
minimal residual disease (23, 24) and latency in viral
infections such as HIV (25–27).
The analytical sensitivity of the measurement of
double stranded DNA molecules can be further en-
hanced by denaturing the molecules prior to partition-
ing (28). Since single strands end up in different
partitions, the analytical sensitivity is improved by a
Fig. 1. Predicted precision and linear range of the Poisson
distribution. Each graph is generated mathematically based
on the Poisson distribution for dPCR reactions with 4 differ-
ent numbers of partitions (n). The majority of dPCR instru-
ments offer reactions where n> 10 000. (A) The relative
uncertainty (based on modeling the 95% upper confidence
limit of k) is highest at the extremes of the range (very few
positive partitions; k/n< 0.1 or very few negative parti-
tions; k/n> 0.95). As the number of partitions in a reaction
increases, so does the precision at a given proportion of
positive partitions. Once n> 10 000 the relative uncer-
tainty is <5% for the majority of the range. Horizontal dot-
ted lines correspond to a relative uncertainty of 5% and
10%. (B) The dynamic range is proportional to the number
of partitions in a reaction, note the dynamic range is
greater than the number of partitions. The horizontal dot-
ted lines correspond to the copies per reaction for each
given n where the relative uncertainty of k is less than
50%.
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factor of two. Other applications that exploit the
unique partitioning of dPCR include cis-trans linkage
relationships between two targets (29–31) and ‘drop-
off’ assays for identifying the frequency of a mutation
of unknown sequence (32), and evaluation of gene
editing efficiency when using approaches like CRISPR-
Cas9 (33).
Furthermore, dPCR provides high reproducibility
to the above technical advantages. This is possible when
the same target is measured in different laboratories (34,
35) using different assays or assay formats (36), or
instruments from different manufacturers (37, 38). This
is also achievable both when measuring purified nucleic
acid, but also whole biological samples in which preana-
lytical steps such as extraction need to be included (36,
39). This characteristic has made dPCR a popular
method to quantify reference materials (40, 41), to sup-
port applied molecular testing in clinical diagnostics
(42–44) and food testing (45–47).
When used to conduct quantitative measurements,
molecular genetic methods have historically applied
mass and mole, combined with volume, to calculate
copy number concentration. Mass or mole are arguably
not ideal when considering a large macromolecule such
as DNA, and nucleic acid calibration materials have
rarely been traceable to the International System of
Units (SI) (48). dPCR has the capability of counting all
intact (equal or larger than the amplicon) DNA mole-
cules containing a specific target sequence (49), thereby
potentially offering SI traceability via counting to the
unit one (48). To maximize the potential impact of
such a capability, efforts have been made to harmonize
and standardize best practices in dPCR (and qPCR) in
the ISO 20395 standard (50).
Quantification accuracy for copy number meas-
urements is dependent on both completeness of molec-
ular count and accurate definition of the unit volume
of sample and total reaction (i.e., number of partitions
of accurately defined volume). Both need to be demon-
strated for claims of SI traceability by dPCR to be sup-
ported. International collaboration among national
metrology institutes, supported by the Consultative
Committee for Amount of Substance: Metrology in
Chemistry and Biology (CCQM), have led research
demonstrating that dPCR can indeed measure with
sufficient accuracy for primary SI-traceability (38, 51).
dPCR has provided the first ever nucleic acid reference
measurement procedure accepted by the Joint
Committee on Traceability in Laboratory Medicine
(JCTLM) (38) and dPCR is included as an example of
a higher order reference measurement procedure within
the new edition of the ISO 17511 guideline on metro-
logical traceability of values assigned to calibrators and
control materials for diagnostic methods (52).
The potential for dPCR to enable new research op-
portunities and to support traceability in the wider field
of molecular genetic measurement should have a major
impact on the accuracy of nucleic acids measurement as
a whole. However, researchers and manufacturers must
tread cautiously to ensure that the nuances that may af-
fect these measurements are understood. What follows
are some steps to consider on this journey.
Considerations for Designing and Performing
dPCR Experiments
Like qPCR, to maximize the performance of dPCR, spe-
cific considerations are required to ensure unbiased and
reproducible measurements (50, 53). The following sec-
tions outline how best to design and perform dPCR
experiments. Sections may be interdependent: for exam-
ple, to determine the false positive rate of an assay, not
only assay design, but selection of control materials and
partition classification are important.
Following dPCR, the end-point fluorescence of
target containing positive partitions is higher fluores-
cence than those without, negative partitions (back-
ground). These fluorescence values can be plotted in
one-color dimension with the fluorescence intensity
against partition number (Fig. 2) or as two-colors
(Fig. 3A–D) or more (Fig. 3E), with the fluorescence
intensity of the different channels aligned to different
axes. Visualization of these plots can aid assay optimi-
zation and quality control.
ASSAY DESIGN AND OPTIMIZATION
dPCR requires the same careful assay design considera-
tions as those required for qPCR (53, 54). Smaller
(<150 bp) amplicons are desirable although larger
products can also be quantified (55). To generate the
fluorescent signal by PCR, probe-based chemistries (e.g.,
hydrolysis probes, ideally with nonfluorescent quenchers)
or DNA binding dyes (e.g., EvaGreen) can be used when
compatible with the dPCR platform.
Assay optimization, by varying the annealing tem-
perature (Fig. 2A) as well as primer and probe concen-
trations (Fig. 2B), is best performed using a template
that closely matches that of the test template, as perfor-
mance may vary with different template types (e.g., plas-
mids, genomic DNA, cell-free DNA, synthetic DNA).
Furthermore, while different batch syntheses of probes
of the same sequence can change the final fluorescence
intensities, this can have a negligible effect on the mea-
sured results (Fig. 2C). Matrix effects and inhibitors
may also reduce the fluorescence intensity of the positive
partitions. While ‘suboptimal’ reactions may provide
similar results to more optimum conditions (Fig. 2D),
reflecting methodological robustness, optimization
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should strive to elevate the positive from the negative
populations, to maximize the ‘peak resolution’ (56) and
reduce the number of partitions in between that are
termed ‘rain’ (see below).
MULTIPLEX ASSAYS
Design criteria for multiplex dPCR are similar to other
multiplex PCR applications. The increased number of
primers and probes requires additional consideration of
complementary sequences to avoid nonspecific hybridi-
zation. Similar to qPCR, multiplexing is performed with
fluorescently-labeled probes that are preferentially
detected in different fluorescence channels (Fig. 3).
The simultaneous analysis afforded by multiplexing
can improve resource efficiency, reduce the amount of
sample needed for analysis (important when the speci-
men is limiting), and allow for direct internal control of
an individual reaction. Multiplex dPCR also has other
advantages; for copy number variants, the pairing of tar-
get and reference genes to determine their ratio arises
naturally using a duplex approach (Fig. 3A) (57, 58).
Similarly, for biallelic variation of single nucleotide var-
iants or small insertion/deletions, typically analyzed
with two hydrolysis probes, a duplex approach visualized
using two color plots is the favored format (Fig. 3B). In
drop-off assays (59), genotype is determined by count-
ing partition numbers from the single and double posi-
tive clusters (Fig. 3C); it is not possible to make this
calculation accurately using single color analyses.
Two color analysis can also be applied to identify
some technical artifacts that may be difficult to discern
with single color analysis. For example, fluorescent bleed
through (also termed crosstalk or spillover) occurs when
signal from one fluorophore is detected in a channel
intended for another. If a duplex experiment is visual-
ized as respective single color plots, fluorescent bleed
through may appear as additional clusters and can be
mistaken for reduced analytical specificity (Fig. 3A; see
red arrow). In multiple color plots, fluorescent bleed
through clearly manifests as a ‘leaning’ or ‘lifting’ of the
single positive partitions away from the intended axes
towards the expected position of the double positive
partitions (Fig. 3A).
Fluorescent bleed through can be determined by
performing single probe reactions, using a template that
only contains the intended target, and visualizing the ex-
periment in two colors. If the clusters ‘lean’ or ‘lift’ into
the other axis, then bleed through is confirmed.
Reducing the concentration of the relevant probe,
changing the fluorophore, and/or applying a color com-
pensation matrix may reduce the bleed through.
Bleed through can often be tolerated as long as its
source is understood. If the ‘lean’ or ‘lift’ is absent when
using a single color reaction, then it suggests that this
may be caused by something else, such as reduced assay
specificity. Probes designed to similar sequences (e.g.,
single nucleotide variants) may bind to the alternate var-
iant, reducing specificity (60). While this may be minor,
a ‘lean’ or ‘lift’ similar to fluorescence bleed through
may occur (Fig. 3B), reducing the peak resolution for
the affected reporter. When an alternative variant is pre-
dominant, as in rare variants within cell-free DNA, false
positive signals caused by factors like PCR errors, will
ultimately limit the lower fractional abundance that can
be measured (see further and Fig. 4).
Another artifact with competing probe duplexes
(59) is a drop in fluorescence in the double positive par-
titions (Fig. 3B). When variants of the same molecule
are amplified by a single primer pair in the same parti-
tion, competitive PCR or partition-specific competition
(PSC) occurs (59). Where different variants are both
present in a partition, they will compete for the primers,
resulting in a reduced fluorescence intensity when com-
pared to partitions containing a single variant. PSC can
occur even when the reaction is performed in singleplex
because if other variants (or pseudogenes with sufficient
homology) are present, they will amplify and compete
with the variant of interest reducing peak resolution. If
the method is performed in duplex and evaluated in a
two-color plot, it is clear that PSC is occurring and
thresholds are easier to set (Fig. 3B). In drop-off assays,
PSC can cause the double positive partitions to appear
as a second cluster with reduced fluorescence intensity
(Fig. 3C). The impact of PSC, fluorescent bleed
through, and other factors can be evaluated using an op-
timization and quality control protocol outlined previ-
ously (59).
In addition to multicolor multiplexing, dPCR can
specifically detect more than one target within an individ-
ual fluorescent channel. This ‘higher order multiplexing’
is achieved by varying the concentrations of different
probes using the same fluorophore (61) (Fig. 3D) or dif-
ferently sized amplicons with DNA binding dyes (62).
Higher order multiplexing can be performed in a single
color, where two different targets are detected within a
single reaction (63), or in multicolor assays that use two
or more probe colors to detect more targets than fluoro-
phores with a single reaction (61).
TEMPLATE
As with all other PCR formats, DNA is the only nucleic
acid that can be measured by dPCR. Like qPCR, tem-
plate complexity may impact assay performance as seen
with circular plasmids and high fragment length geno-
mic DNA (37). Restriction digestion to small linear
DNA fragments may equalize template differences (36,
49, 64), and prevent underestimation of linked target
molecules (18). However, restriction sites must not be
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Fig. 2. Examples of the one color plot outputs demonstrating methodological robustness. The same assay and genomic DNA
template is used in all parts of the figure. Unless otherwise stated, each reaction contains 900nM of each primer and 250nM of
probe, annealing temperature: 60C, run for 40 PCR cycles. (A) The effect of the annealing temperature (gradient 65C to 52C
from left to right) on the final fluorescence intensity of the positive and negative partitions. Each reaction contains approxi-
mately 20000 copies of the gDNA template analyzed using the QX200 (Bio-Rad) with Supermix for probes (no dUTP) (Bio-Rad).
The horizontal pink line represents the threshold to separate the positive and negative partitions. (B) The effect of primer and
probe concentrations on the difference in fluorescence intensity between positive and negative partitions. Reactions 1-3 have
250, 500, and 1000nM of primer, respectively, all with 50nM of probe. Reactions 4-6 have 250, 500, and 1000nM of primer,
respectively all with 250nM of probe. Each reaction contains approximately 40000 copies of the gDNA template analyzed using
the Naica (Stilla) and Perfecta Multiplex qPCR Toughmix (Quanta BioSciences). The blue horizontal lines represent the threshold
to separate the positive and negative partitions. (C) The difference in fluorescence intensity of positive and negative partitions
between 6 different batches of the same assay purchased between 2012 and 2017 from 3 different manufacturers. The genomic
DNA template concentration and dPCR platform is the same as that described in (A). (D) Comparison of the copy number concen-
trations calculated from each of the 18 reactions shown in (A)-(C). Each reaction is represented by a symbol in the order it
appears in its respective color plot.
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Fig. 3. Examples of two and three color plot outputs using different multiplex format demonstrating leaning, lifting and parti-
tion specific competition.
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present in the amplicon sequence, and digestion of al-
ready fragmented DNA (e.g., from formalin-fixed, par-
affin embedded tissues or cell-free DNA) may result in a
loss of signal (36).
RNA transcripts can only be measured by first con-
verting to complementary DNA (cDNA) in reverse
transcriptase digital PCR (RT-dPCR) using either one-
or two-step formats. In a one-step strategy, RNA is par-
titioned with both reverse transcription and PCR occur-
ring sequentially in the same partition. Even if multiple
cDNA copies are generated from each RNA molecule,
results are not overestimated. In two-step reactions, re-
verse transcription is first performed in bulk before par-
titioning the cDNA and subsequent dPCR in a separate
reaction. The reverse transcriptase step can be a predom-
inant source of error that should be considered during
experimental design (65).
While newer dPCR formats have greater dynamic
ranges, they cannot compete with qPCR, which is typi-
cally capable of over 6 orders of magnitude.
Consequently, in certain situations a prior knowledge of
the template concentration may be required to avoid
saturating the instrument. When concentrations are
sufficiently high, commonly used methods, such as
those that employ fluorometry and spectrophotometry,
can be used to quantify nucleic acids and guide the dilu-
tion to concentrations for optimal measurement using
dPCR. It should be noted that such methods estimate
mass per unit volume of the component nucleic acid
bases not the macromolecule. Consequently, determina-
tion of genome copies using approaches that measure
mass requires knowledge, or assumptions, of template
composition, purity, and quality to convert mass to
moles. Users should also be aware of potential interfer-
ing factors that may disrupt the accuracy of such optical
methods. When comparing mass-based nucleic acid
quantification with dPCR results, or those from any
method used to calculate molecular copy number, a
clear description of the molecular weight of the genome
used to calculate the genome equivalents must be in-
cluded, along with the method used to calculate this
value.
PREANALYTICS
While dPCR can be accurate, performance depends on
the amount of template added to the reaction. Error
Fig. 3. (Continued) Parts A-D of the figure have been generated using the QX200 (BioRad); each part shows a two color scatter
plot with the corresponding single color plots orientated along the corresponding axis (channel 1 (Ch1); y-axis, and channel 2
(Ch2); x-axis). The horizontal and vertical pink lines represent the thresholds for Ch1 and Ch2, respectively. Part E of the figure
has been generated using the Naica (Stilla); a three color plot is shown with the three axes orientated as the blue channel (x-
axis), red channel (y-axis), and green channel (z-axis). The 3 thresholds are not displayed for aesthetic purposes. The correspond-
ing two color plots are presented in Supplemental Fig. S2. (A) Noncompeting duplex reaction (for definition of multiplex formats
see (59)) containing separate primer pairs for each amplicon. The ratio between the 2 targets is !1.6. The partition clusters are
colored based on their classification: blue; Ch1 positive only, green; Ch2 positive only, orange; double positive (both Ch1 and
Ch2) and gray; double negative. Example of fluorescent bleed through is evident with the ‘leaning’ of the blue cluster in the
two color plot that appears to show additional negative cluster (red arrow) in the green single color pot. (B) Competing duplex
reactions containing a single primer pair with different probes targeting two different single nucleotide variants. The mutant tar-
get (blue) is approximately 1% of the wild type target (green). The clusters are colored as described in (A). Evidence of PSC is
shown in the orange cluster that forms an ‘arc’ instead of the defined orange cluster observed in (A). Indication of reduced probe
specificity is shown as the ‘leaning’ and ‘lifting’ of the blue and green clusters, respectively. (C) Drop-off assay containing a sin-
gle primer pair with different probes that bind to different region of the same amplicon. The two targets are in approximate
equal numbers. The clusters are colored based on their classification; variant only (green), wild type and double positive (or-
ange). Evidence of PSC is shown with a smaller orange cluster (within dotted red circle), this cluster contains wt and variant dou-
ble positives partitions while the larger orange cluster contains wt partitions only. (D) Higher order multiplexing reaction to
measure three targets in 2 fluorescent channels; 2 targets (T1 and T2) in Ch1 and 1 target (T3) in Ch2. Each is with a different
primer pair and at approximately 1:2:1 ratios as T1: T2: T3. Clusters are colored based on their classification: purple; T1 positive
only, red; T2 positive only, green; T3 positive only, pink; T1 and T3, black; T2 and T3, blue; T1 and T2, orange; T1, T2 and T3. (E)
Three color non-competing triplex reaction containing separate primer pairs for each amplicon. The ratio between the 3 targets
is !1. The partition clusters are colored based on their classification: dark blue; blue positive only, green; green positive only,
red; red positive only; cyan; double positive (both blue and green), yellow; double positive (both green and red); purple; double
positive (both blue and red), light grey; triple positive (blue, green and red) and dark grey; triple negative. Fluorescent bleed
through has been corrected using an assay specific compensation matrix experiment as recommended by the instrument
manufacturer.
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introduced during steps prior to dPCR (such as from ex-
traction, template modification, or reverse transcription)
will impact on results. To describe error, we refer to the
International Vocabulary of Metrology (66) where error
may be random (impacting on precision) or systematic
(impacting on trueness leading to bias). dPCR can be
highly precise with the potential to measure minute dif-
ferences. However, if the preanalytical error is large, ac-
curacy (closeness of agreement between measured
quantity value and the true quantity value (66), in terms
of both precision and bias) will be compromised and in-
correct conclusions generated. This may manifest in a
dPCR reaction as a result of both suboptimal quantity
and quality of the extracted nucleic acids.
Therefore, the preanalytical precision and bias of
any dPCR assay should be measured and, where appro-
priate, incorporated into the conclusions. Replication of
the whole procedure (e.g. by repeating the extraction
on multiple samples) should be used to estimate random
error. Process controls for specific protocol steps may be
necessary to reveal systematic errors related to extrac-
tion, enrichment, modification, and reverse transcrip-
tion. Conveniently, the precision of dPCR makes it an
ideal tool to assess preanalytical procedures, and has
been applied to nucleic acid isolation (36), massively
parallel sequencing library preparation (67, 68), reverse
transcription efficiency (69), preamplification (57), and
genome editing using methods like CRISPR-Cas9 (70).
EXPERIMENTAL CONTROLS AND CALIBRATION
Although dPCR is far simpler to calibrate than qPCR, it
should not be assumed to be ‘calibration free’. External
calibration may be necessary to identify biases in preana-
lytical steps and where used, calibrators should perform
similarly to the samples of interest. Internal calibration,
or normalization, is often used by reporting results as
percentages, ratios, fractional abundances, or normalized
copies. For ctDNA, variants are often expressed as a var-
iant allelic frequency or fractional abundance relative to
the sum of both wild type and variants sequences.
However, even in this case, reporting the absolute DNA
concentration is also important because it may directly
affect the observable false positive rate (Fig. 4) and pro-
vides an idea of what can be expected in terms of preci-
sion and analytical sensitivity. Although normalization
to total nucleic acid concentration may be appropriate,
other denominators can be used, such as biofluid vol-
ume used historically for viral load measurements and
increasingly in oncology for ctDNA measurement.
Importantly, the identity and rationale for control and/
or calibration strategy should be clearly described.
A variety of control reactions are necessary in
dPCR. Negative control reactions that contain the reac-
tion mix, including primers and probes, but do not the
nucleic acid template can identify cross contamination
between samples, as well as carry-over contamination
from previous amplified product. If DNA concentra-
tions are high, a few negative controls may be adequate
to monitor for cross contamination. However, for low
copy number ‘trace’ analysis, a larger number of nega-
tive controls randomly included amongst the samples of
interest will have a better chance of identifying results
that are derived from false positive partitions.
An equally important negative control for inclusion
in dPCR experiments is the same DNA/RNA back-
ground, but without the targeted sequence. These con-
trols can assess specificity as well as contamination. This
is particularly important when measuring rare genetic
variants in samples that contain predominantly wild-
type sequence. The frequency of low level false positive
results (Fig. 4) defines the limit of detection or quantifi-
cation and may aid in the setting of thresholds.
Furthermore, when measuring real samples, extract
quality can impact on the fluorescence intensity which
can lead to variations in peak resolution.
While negative controls are essential, positive controls
that ideally reflect real samples in complexity, integrity, pu-
rity, and concentration are also important. dPCR is less
susceptible to inhibition, but is not immune (71). Internal
positive controls (50) confirm negative results and are es-
sential when dPCR is used in clinical diagnostics. Positive
controls (both internal and external) of defined concentra-
tion provide quality assurance and are particularly useful
when evaluating the preanalytical steps. The number of
positive partitions in low-level trace analysis may be so low
that the appropriate threshold setting is best determined
from a more concentrated positive control.
Considerations for Data Analysis
For dPCR results to follow the Poisson distribution, a
number of conditions must be met (60, 72). There needs
to be 1) clear discrimination between positive and negative
partitions; 2) partitions of equal defined volume; and 3)
random distribution of target molecules among partitions.
These conditions are not always met in practice, and con-
sequently each step of the dPCR data analysis pipeline
should be described (60, 72) with representative examples
of the raw data published as Supplemental material. A typ-
ical dPCR analysis pipeline involves 1) classification of par-
titions as positive or negative; 2) determining k using the
proportion of negative (or positive) partitions based on
Poisson statistics (Equation 1 below); 3) processing of rep-
licate reactions; and 4) normalization and/or rescaling.
Throughout the analysis, it is important to correctly propa-
gate errors to report the uncertainty of the final values (58)
and to account for system specific technical factors that
may influence accuracy (72).
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CLASSIFICATION OF THE PARTITIONS
Partitions are classified by setting thresholds that separate
the different clusters of partitions based on their
fluorescent intensity. If instruments also provide real time
PCR plots for each partition, the shape of the sigmoidal
amplification curves can also be used to aid classification.
Fig. 4. An example of false positive rate of a single nucleotide variant assay. Example of the KRAS G12D mutation using the
PrimePCR dPCR assay (Bio-Rad) and Supermix for probes (no dUTP) (Bio-Rad) using the QX200 (Bio-Rad) as described in (38). All
reactions were performed in triplicate within a single experiment. (A) A 15-point two-fold serial dilution series from !300 to
!5 million copies of the linearized KRAS wt plasmid was analyzed for G12D variant false signal to determine the false positive
rate (FPR) over the wt dynamic range. FPR is linked to wt concentration with too few (<1200) or too many wt molecules
(>625 000) per reaction reducing the visible FPR. The horizontal dashed line represents the published FPR for this assay (38)
that is quantifiable between 12 000 to 100 000wt copies per reaction. (B) The corresponding copy number counts for the KRAS
wt and G12D variant are shown. This demonstrates linearity in the wt measurements over the dynamic range (with quantities
>60 000 being affected by saturation), and false G12D measurements associated with wt concentration. Examples of the two-
color plots from the experiment of (C) a single well for the 39 000wt copies/reaction showing the location of the false positive
G12D partitions (orange) with the negative (grey) and wt only (green) clusters and (D) a positive control reaction using the 5%
allelic frequency of the Multiplex I cfDNA Reference Standard Set (Horizon Discovery) to show the location of the single positive
G12D cluster (blue). The pink lines represent the threshold to separate the positive and negative partitions and are at the same
fluorescence intensity for C and D.
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Each cluster of partitions is assigned as either containing
or not-containing target molecules. Multiple partition
classification strategies have been developed, including
manual and automated procedures with either linear or
nonlinear methods (e.g., polygonal gates). Some methods
are confined to singleplex assays whilst others can handle
multiplex multicolor formats and it may not always be
necessary to identify all partition clusters (59).
SETTING MANUAL THRESHOLDS FOR SINGLEPLEX ASSAYS
Manual classification is simple and effective for well-
optimized assays that have a clear difference in fluores-
cence intensity between the positive and negative parti-
tions. However, as complexity associated with the
template, assay, and degree of multiplexing increases,
manual strategies can be challenging to reproduce and
may introduce operator bias. Different batches of probes
targeting the same sequence can change the peak resolu-
tion (Fig. 2C) and thresholds may need to be re-
defined. Experiment reports should include the method
of manual threshold setting. Analysis by multiple opera-
tors is preferred, followed by result comparison to reveal
the associated variation. Graphical display of positive
and negative controls with their threshold settings
should be included in Supplemental material.
AUTOMATED THRESHOLD SETTING
Automated threshold settings can limit bias and increase the
robustness of data analysis and reporting. Multiple strategies
have been developed by both instrument manufacturers and
independent software developers. Each has specific features
and assumptions. Statistical strategies include clustering
methods (73–79), implementation of extreme value theory
(80), and reliance on parametric distributions (56, 81, 82).
Automated partition classification methods are only valid if
the data fits the assumed distribution (73, 74, 81, 82). Prior
statistical analysis (i.e., Kolmogorov-Smirnov) should be per-
formed to help determine the method of choice.
Alternatively, ddpcRquant or Umbrella work independently
of distribution assumptions (78, 80).
RAIN
The ideal dPCR scatter plot has clear space between
positive and negative partitions (Fig. 2). However, parti-
tions with intermediate fluorescence, defined as ‘rain’
are frequently observed (Fig. 5). Rain often results from
reduced amplification efficiency that can be caused by
several factors, including template accessibility (83),
suboptimal annealing temperature (84), PCR inhibitors
(85), and mismatches between the assay and the target
sequences (80). Studies with probes suggest that longer
elongation times, higher cycle numbers, and optimal
annealing temperatures may effectively reduce rain (86),
and that rain assigned to the positive fraction can
improve accuracy (Fig. 5C) (25, 87–89). Hence, these
‘rainy’ partitions likely contain genuine target sequences
and exclusion may lead to a negative bias, especially in
cases with trace target, PCR inhibition, or high se-
quence variation. However, users should investigate rain
where it is a problem to establish whether to include it
during analysis; there are a variety of methods and tools
that can assist in this process (74, 76–78, 80).
CALCULATION OF COPY NUMBER CONCENTRATION
Two assumptions for dPCR to fit the Poisson distribution
are that all partitions are of equal volume, and that target
molecules are randomly distributed across partitions (60,
72). In practice, this means that each partition has an equal
chance of containing target molecules (90). The number of
target molecules present within positive partitions may be
one, two, or more molecules, and it is currently impossible
to determine how many molecules a given positive partition
may contain. By contrast, the number of molecules in a
negative partition is known. If all partitions are of equal vol-
ume, the mean concentration of target molecules per parti-
tion (k) can be estimated from the probability that a
partition is negative using the proportion of negative parti-
tions and the Poisson distribution (Eq. 1). This concentra-
tion is derived from the number of negative partitions (w)
and the total number of partitions in the reaction (n):
k ¼ #ln w
n
! "
(1)
An equivalent form using the number of positive
partitions (k):
k ¼ #ln 1# k
n
! "
(2)
The simplicity of determining the number of target
molecules in this way is one of the strengths of dPCR.
Once k has been calculated, there are a number of down-
stream calculations that can be made. To calculate the
sample concentration (C) of target molecules per unit
volume, the most straightforward method uses (Eq. 3),
where Vp is the average volume of a partition and D the
dilution factor of the sample in the dPCR reaction (91)
C ¼ k$ 1
Vp
! "
$D (3)
Equation 3 determines the number of target mole-
cules per unit volume of the sample extract measured by
the dPCR. Reporting concentration per sample extract
is recommended as it is agnostic to the method used
and simplifies comparison.
IMPACT OF PARTITION VOLUME AND VOLUME VARIATION
Current dPCR instrument use predefined partition vol-
umes from the manufacturer that are averaged figures
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with no uncertainty value incorporated into the soft-
ware. Independent validation experiments have revealed
that the partition volumes are not constant (37, 40, 83,
91–93). The partition volumes (either assumed or di-
rectly measured), and software versions, used should be
reported. In addition, volume variance among partitions
can result in quantification bias underestimating the tar-
get DNA concentration (60, 72). Methods to compen-
sate for partition volume variability are available (60,
93–95). The associated bias is greater at higher concen-
trations (k> 2) (72). A dilution series of template will
show a negative bias at higher concentrations if partition
volume variance is causing bias (94).
ESTIMATION OF RANDOM ERROR
The binary output of positive and negative partitions
follows a binominal distribution, which by definition
has a known variance. This theoretical variance in
dPCR is often referred to as Poisson error (96). Poisson
error is only effective at estimating random error well if
the number of positive partitions is sufficiently large and
if k is not extremely low or extremely high (97).
Furthermore, Poisson error does not include experimen-
tal sources of variance among reactions, such as pipet-
ting errors and sampling variation (72). When errors
from multiple sources are combined, the total combined
variance should be reported as the uncertainty of the fi-
nal concentration determination (e.g., using the method
from Section 3 in the Supplemental Material 4 from
(58)). For these reasons, the variation of replicate
Fig. 5. Inclusion of the rain in the positive fraction of the
partitions. (A) A six-point two-fold serial dilution of genomic
DNA was prepared.
Fig. 5. (Continued) dPCR was performed using the QX200
(Bio-Rad) with the Evagreen supermix (Bio-Rad) and
100 nM of each primer that targets a human endogenous
retrovirus (HERV-K) target with an amplicon of 80 bp. The
annealing temperature was 60 %C and 40 PCR cycles of the
recommended Evagreen cycling protocol were performed.
The horizontal pink line represents the threshold to sepa-
rate the positive (blue) and negative (grey) partitions that
includes the rain in the positive fraction of the partitions
(threshold ¼ 6068; as shown in the figure). (B) The same
reactions wells as shown in (A) but with the threshold set
high to exclude the rain from the positive fraction of the
partitions (threshold ¼ 13482; as shown in the figure). (C)
Copy number concentration of the serial dilution either in-
cluding (red triangles) or excluding (black triangles) the
rain in the positive fraction with the threshold number indi-
cated. A systematic bias of 17% resulting in underestima-
tion of the copy numbers was observed when excluding the
rain from the copy number calculation.
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experiments used in the analysis should be reported in-
stead of only relying on Poisson error.
EXPERIMENTAL DATA SHARING TO SUPPORT TRANSPARENCY
It is important that experimental analysis can be assessed
independently; this is best provided by sharing the raw
data so that analyses can be reproduced. This can be
done by sharing run files or, to account for the fact that
data formats are generated by different instruments,
converting the raw dPCR data into Real-Time PCR
Data Markup Language (RDML)(98). The latest 1.3
version of RDML, originally developed for qPCR data,
now includes dPCR data. The digital raw data are col-
lected in a spreadsheet format and linked to the
Extensible Markup Language part of the RDML file
that holds the counts for positive and negative partitions
allowing reanalysis. Files should be made available either
on request or preferably as Supplemental files or on an
online repository, such as RDMLdb (99). If data is not
available for sharing, authors need to explain why.
The Digital MIQE 2020 Guidelines
(dMIQE2020)
The original MIQE and dMIQE guidelines compiled a
list of both essential and desirable information for
articles applying qPCR or dPCR, respectively. For sim-
plicity this format has been revised, and dMIQE2020
only requires the essential information needed to be in-
cluded when publishing research using dPCR. For
authors, this information can be presented either within
the main text or as Supplemental information; a blank
dMIQE2020 table is provided for this purpose
(Supplemental Table 1). A further update to the table is
the inclusion of a new comments section within the
checklist for notes and rationale when particular items
may not be applicable.
To further support uptake and provide an example
of how to complete the table, we have completed the
dMIQE2020 table (Supplemental Table 2) for the
dPCR experiments performed to generate Figs. 2, 4 and
5 presented in this publication. Supplemental informa-
tion describing the materials, methods and data used
to generate these figures is also provided (online
Supplemental Information file).
The dMIQE2020 checklist (Supplemental Table
1) includes the following sections:
SPECIMEN
The specimen is the material taken to be analyzed.
Often, only a portion of the specimen, the sample, is
analyzed. It is essential that details are provided of
what the specimen and sample are and how they were
collected; including description of any treatment such
as snap freezing or the addition of EDTA to blood.
Factors such as volume or mass of the specimen(s) are
simple to describe. Sampling procedure, including type
of container, handling, and storage conditions, as well
as subsampling, must be described because they may
result in variation among laboratories. These proce-
dures, and those for nucleic acid extraction (see follow-
ing section), are being standardized by the European
Union funded consortium SPIDIA4P from which
European Committee for Standardization (CEN) and
International Organization for Standardization (ISO)
guidelines are being developed.
NUCLEIC ACID EXTRACTION
Extraction is one of the most crucial preanalytical steps
that influences dPCR because it is a major factor in dic-
tating how much nucleic acids are available and present
for analysis. Extraction provides two roles prior to mo-
lecular analysis. First, nucleic acids are purified, inhibi-
tors removed, and dissolved/eluted in a suitable buffer.
Second, nucleic acids can be concentrated, improving
analytical sensitivity. It is vital that information about
the amount of sample extracted, the amount and type of
buffer the resultant nucleic acids were eluted/dissolved
in, and any variations applied to the protocol are de-
scribed. Simply stating that the extraction method was
“according to the manufacturer’s protocol” is not
sufficient.
NUCLEIC ACID ASSESSMENT AND STORAGE
Once the nucleic acid is extracted, it is usually charac-
terized and stored prior to analysis. If initial
quantification by total nucleic acid measurement meth-
ods (spectrophotometry or calibrated fluorimetry) is
performed to guide subsequent template addition,
details must be described. Fragment size or differential
amplicons (100) can be assessed by electrophoresis,
and quality metrics may support methodological
understanding.
Nucleic acid storage conditions should be reported.
A description of temperature, concentration, duration,
buffer, and pH, and whether any aliquots were made is
essential. While there are many ways to store nucleic
acids, stability should be verified when nucleic acids are
stored for long (>1month) periods of time. While
DNA can often be directly measured by dPCR after ex-
traction, dilution of concentrated samples may be neces-
sary to prevent dPCR saturation and this should be
described if performed. When working with samples of
low concentration, material may be lost due to adsorp-
tion to container walls, pipette tips, etc. The use of car-
rier or protective solutions can reduce this effect.
Furthermore, repeated freeze-thawing of the sample
should be avoided.
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NUCLEIC ACID MODIFICATIONS BEFORE DPCR
The application of methods for modification of
extracted templates, such as fragmentation of genomic
DNA, must be described. Any preliminary methodolog-
ical development outlining performance, or associated
references, need to be included. DNA modifications,
such as bisulfite treatment for assessment of DNA meth-
ylation, must be described in detail along with any sub-
sequent dilution and/or purification.
REVERSE TRANSCRIPTION
Along with extraction, the reverse transcription step is a
major source of uncertainty and potential bias (65,
101). When conducting reverse transcription, details in-
cluding the choice of the RT and its concentration, the
amount of RNA, incubation temperature and duration,
primer concentration, and priming strategy must be de-
scribed. When conducting two-step RT-dPCR, a de-
tailed description of the separate reverse transcription
reaction must be described. Furthermore, when con-
ducting two-step protocols, it is essential to provide a
clear description of dilution and/or additional purifica-
tion steps performed following the reverse transcription
step prior to adding the cDNA to the dPCR. Reactions
that do not include the RT step (RT negatives) are im-
portant to control for DNA contamination that may
also be detected and incorrectly measured as cDNA by
the RT-dPCR if not defined.
DPCR OLIGONUCLEOTIDES DESIGN AND TARGET
INFORMATION
It is essential that information concerning assay design
and rationale is provided. Identification of the intended
target, including the sequence accession number or offi-
cial gene symbol, and the location of the amplicon is
critical. The specific oligonucleotide sequences are im-
portant to include as they are the fundamental compo-
nents that determine an assays sensitivity and specificity.
If these are not available, as with some commercial
assays, the amplicon context sequence should be pro-
vided (102). Detailed data on assay sensitivity and spe-
cificity should also be included. Without this
information, validity cannot be ensured by the scientific
community.
DPCR PROTOCOL
dPCR can perform measurements with high reproduc-
ibility and minimal bias resulting in high accuracy (38).
Such characteristics increase the chances that results will
be corroborated and of value to the scientific commu-
nity. Reaction protocol information is essential to in-
clude within a manuscript describing results from dPCR
experiments. dPCR requires the preparation of pre-
reaction mixtures prior to partitioning and a detailed
description of its components, including its volume and
the proportion (and total nucleic acid concentration) of
template added is needed. It is important to consider
the likely final reaction volume (the partition number
multiplied by the partition volume) and not the prereac-
tion volume when considering experimental design.
This especially important when measuring low concen-
trations of target as the difference between reaction vol-
ume and prereaction volume (termed dead volume) can
be large depending on instrument format. Reporting of
additional components, such as oligonucleotide concen-
trations and reaction thermal cycling parameters, are es-
sential for all forms of PCR.
ASSAY VALIDATION
Details of how optimization was performed, such as dif-
ferent temperatures and/or oligonucleotide concentra-
tions used, should be reported, along with pass/fail
criteria. It is important to describe analytical specificity
and sensitivity and how these parameters were evaluated
during experimental validation (for example, choice of
control materials). Assessment of analytical specificity
varies depending on application and can be influenced
by related species (pathogen diagnostics) or endogenous
DNA (rare variant detection). Ultimately researchers
must be confident that the assay is providing accurate
negative and positive results and be cognizant of when
this may not be the case.
DATA ANALYSIS
The experimental design should be described, along
with the positive and negative controls employed.
Examples of positive and negative controls should be in-
cluded within the publication either in the main body
or Supplemental information. When false positive sig-
nals are considered acceptable, background examples of
these plots should also be included, as well as informa-
tion outlining how this was considered in the data
analysis. Positive and negative controls should serve for
assay quality control and threshold setting; they can also
be used to identify bias or systematic error in dPCR
measurements and preanalytical steps, where suitable
materials exist.
Technical replication of biological samples or con-
trols should be described, with the data generated form-
ing the basis of estimation of repeatability and
reproducibility, reflecting sources of random variation.
Repeatability and reproducibility (66) may also be esti-
mated based on experiments performed during assay val-
idation. Replication of the entire experimental process
(i.e., replicating samples from the specimen, thus in-
cluding all preanalytical steps such as extraction and,
when measuring cDNA, reverse transcription) is the
best estimate for random error of a given measurement.
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Bias or systematic error is more challenging to character-
ize, but control materials can be used to identify the ex-
tent of bias and variation in dPCR measurements and
preanalytical steps.
Compiling, normalizing/rescaling, and analyzing
the reported dPCR results need to be detailed. The aver-
age number and range of the measured partitions is nec-
essary because when this is combined with the partition
volume, it provides the actual volume of a given dPCR
reaction. dPCR is best initially analyzed using lambda
(k) that can be used to quantify the DNA (or cDNA)
concentration of the sample (see Eq. 3). Even when rela-
tive amounts, such as fractional abundance are used, k
of the respective targets should also be reported. The
ability to report absolute values is unique to dPCR, pro-
vides valuable additional information about the experi-
ment and should be included in Supplemental material
if not in the main text.
Statistical methods and rationale must be described.
To aid transparency and evaluation of conclusions, data
should be available either on request or preferably as
Supplemental manuscript files or in an online reposi-
tory, such as RDMLdb (99).
Conclusions
The purpose of the different MIQE publications (1, 54,
102–108) is to support authors, editors, and reviewers
of manuscripts applying PCR to nucleic acid measure-
ment. The research community can use this as a re-
source to ensure sufficient detail is published to allow
full assessment of the work, while also providing basic
guidance on how to approach experimental design, exe-
cution, and data-analysis.
The goals of the MIQE series of manuscripts
remains three-fold:
1. To enable authors to design, perform, and report experi-
ments that have greater scientific integrity.
2. To facilitate replication of experiments described in pub-
lished studies where these guidelines are followed.
3. To provide critical information that allows reviewers, edi-
tors, and the wider scientific community to measure the
technical quality of submitted manuscripts against an
established standard.
dMIQE2020 describes optimal reporting of dPCR find-
ings to enhance its scientific impact and maximize the
potential of this powerful and unique technology. The
ultimate aim is to ensure that published research apply-
ing dPCR will be understood from a technical point-of-
view and can be reproduced. This in turn supports the
validity of associated conclusions and their successful
translation for use in applied situations, such as in vitro
diagnostic testing.
Disclaimer
Certain commercial equipment, instruments, or materials
are identified in this document in order to describe the
technology they support. Such identification is neither
intended to imply recommendation nor endorsement by
the authors nor their affiliated institutions, nor is it
intended to imply that the materials or equipment identi-
fied are necessarily the best available for the purpose.
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